{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:47:15Z","timestamp":1790628435467,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07312-2","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:10:54Z","timestamp":1781241054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retinal and optic nerve measures after initiation of empagliflozin plus metformin versus metformin alone in early type 2 diabetes: a prospective observational comparative study"],"prefix":"10.1007","author":[{"given":"Bora Deniz","family":"Argon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ak\u0131n","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezin Do\u011fan","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidan","family":"Safal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Nuri","family":"El\u00e7io\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Ada\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"7312_CR1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2337\/db09-9028","volume":"58","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773\u2013795. https:\/\/doi.org\/10.2337\/db09-9028","journal-title":"Diabetes"},{"key":"7312_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/diaclin.26.2.77","volume":"26","author":"MJ Fowler","year":"2008","unstructured":"Fowler MJ (2008) Microvascular and macrovascular complications of diabetes. Clin Diabetes 26:77\u201382. https:\/\/doi.org\/10.2337\/diaclin.26.2.77","journal-title":"Clin Diabetes"},{"key":"7312_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124\u2013136. https:\/\/doi.org\/10.1016\/S0140-6736(09)62124-3","journal-title":"Lancet"},{"key":"7312_CR4","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1126\/science.1957169","volume":"254","author":"D Huang","year":"1991","unstructured":"Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W et al (1991) Optical coherence tomography. Science 254:1178\u20131181. https:\/\/doi.org\/10.1126\/science.1957169","journal-title":"Science"},{"key":"7312_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.preteyeres.2007.07.005","volume":"27","author":"W Drexler","year":"2008","unstructured":"Drexler W, Fujimoto JG (2008) State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res 27:45\u201388. https:\/\/doi.org\/10.1016\/j.preteyeres.2007.07.005","journal-title":"Prog Retin Eye Res"},{"key":"7312_CR6","first-page":"225","volume":"7","author":"J Heravian","year":"2012","unstructured":"Heravian J, Ehyaei A, Shoeibi N, Azimi A, Ostadi-Moghaddam H, Yekta AA et al (2012) Pattern visual evoked potentials in patients with type II diabetes mellitus. J Ophthalmic Vis Res 7:225\u2013230","journal-title":"J Ophthalmic Vis Res"},{"key":"7312_CR7","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.3390\/ijms24087361","volume":"24","author":"G Miura","year":"2023","unstructured":"Miura G (2023) Visual evoked potentials for the detection of diabetic retinal neuropathy. Int J Mol Sci 24:7361. https:\/\/doi.org\/10.3390\/ijms24087361","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"7312_CR8","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee (2026) 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142026. Diabetes Care 49(Suppl 1):S183\u2013S215. https:\/\/doi.org\/10.2337\/dc26-S009","journal-title":"Diabetes Care"},{"key":"7312_CR9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854\u2013865. https:\/\/doi.org\/10.1016\/S0140-6736(98)07037-8","journal-title":"Lancet"},{"key":"7312_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E et al (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159:262\u2013274. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00007","journal-title":"Ann Intern Med"},{"key":"7312_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"7312_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"7312_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"7312_CR14","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","volume":"37","author":"A Piperidou","year":"2019","unstructured":"Piperidou A, Sarafidis P, Boutou A, Thomopoulos C, Loutradis C, Alexandrou ME et al (2019) The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 37:1334\u20131343. https:\/\/doi.org\/10.1097\/HJH.0000000000002050","journal-title":"J Hypertens"},{"key":"7312_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.33594\/000000178","volume":"53","author":"L Uthman","year":"2019","unstructured":"Uthman L, Homayr A, Juni RP, Spin EL, Kerindongo R, Boomsma M et al (2019) Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells. Cell Physiol Biochem 53:865\u2013886. https:\/\/doi.org\/10.33594\/000000178","journal-title":"Cell Physiol Biochem"},{"key":"7312_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4093\/dmj.2017.0095","volume":"42","author":"KA Lee","year":"2018","unstructured":"Lee KA, Jin HY, Lee NY, Kim YJ, Park TS (2018) Effect of empagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on kidney and peripheral nerves in streptozotocin-induced diabetic rats. Diabetes Metab J 42:338\u2013342. https:\/\/doi.org\/10.4093\/dmj.2017.0095","journal-title":"Diabetes Metab J"},{"key":"7312_CR17","doi-asserted-by":"publisher","first-page":"113222","DOI":"10.1016\/j.biopha.2022.113222","volume":"152","author":"Q Gong","year":"2022","unstructured":"Gong Q, Zhang R, Wei F, Fang J, Zhang J, Sun J et al (2022) SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db\/db mice. Biomed Pharmacother 152:113222. https:\/\/doi.org\/10.1016\/j.biopha.2022.113222","journal-title":"Biomed Pharmacother"},{"key":"7312_CR18","doi-asserted-by":"publisher","first-page":"BSR20212209","DOI":"10.1042\/BSR20212209","volume":"42","author":"J Matthews","year":"2022","unstructured":"Matthews J, Herat L, Rooney J, Rakoczy E, Schlaich M, Matthews VB (2022) Determining the role of SGLT2 inhibition with empagliflozin in the development of diabetic retinopathy. Biosci Rep 42:BSR20212209. https:\/\/doi.org\/10.1042\/BSR20212209","journal-title":"Biosci Rep"},{"key":"7312_CR19","doi-asserted-by":"publisher","first-page":"108472","DOI":"10.1016\/j.jdiacomp.2023.108472","volume":"37","author":"S Gullaksen","year":"2023","unstructured":"Gullaksen S, Vernstr\u00f8m L, S\u00f8rensen SS, Funck KL, Petersen L, Bek T et al (2023) Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: a prespecified secondary analysis of a randomised clinical trial. J Diabetes Complications 37:108472. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108472","journal-title":"J Diabetes Complications"},{"key":"7312_CR20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4093\/dmj.2022.0221","volume":"47","author":"TY Lin","year":"2023","unstructured":"Lin TY, Kang EY, Shao SC, Lai EC, Garg SJ, Chen KJ et al (2023) Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Diabetes Metab J 47:394\u2013404. https:\/\/doi.org\/10.4093\/dmj.2022.0221","journal-title":"Diabetes Metab J"},{"key":"7312_CR21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"7312_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"7312_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","volume":"133","author":"JV Odom","year":"2016","unstructured":"Odom JV, Bach M, Brigell M, Holder GE, McCulloch DL, Mizota A et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 133:1\u20139. https:\/\/doi.org\/10.1007\/s10633-016-9553-y","journal-title":"Doc Ophthalmol"},{"key":"7312_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","volume":"188","author":"F Li","year":"2019","unstructured":"Li F, Thomas LE, Li F (2019) Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 188:250\u2013257. https:\/\/doi.org\/10.1093\/aje\/kwy201","journal-title":"Am J Epidemiol"},{"key":"7312_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/00031305.2000.10474549","volume":"54","author":"JS Long","year":"2000","unstructured":"Long JS, Ervin LH (2000) Using heteroscedasticity consistent standard errors in the linear regression model. Am Stat 54:217\u2013224. https:\/\/doi.org\/10.1080\/00031305.2000.10474549","journal-title":"Am Stat"},{"key":"7312_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x","journal-title":"J R Stat Soc Ser B"},{"key":"7312_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11892-021-01428-x","volume":"21","author":"MM Sachdeva","year":"2021","unstructured":"Sachdeva MM (2021) Retinal neurodegeneration in diabetes: an emerging concept in diabetic retinopathy. Curr Diab Rep 21:65. https:\/\/doi.org\/10.1007\/s11892-021-01428-x","journal-title":"Curr Diab Rep"},{"key":"7312_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4239\/wjd.v1.i2.57","volume":"1","author":"M Villarroel","year":"2010","unstructured":"Villarroel M, Ciudin A, Hern\u00e1ndez C, Sim\u00f3 R (2010) Neurodegeneration: an early event of diabetic retinopathy. World J Diabetes 1:57\u201364. https:\/\/doi.org\/10.4239\/wjd.v1.i2.57","journal-title":"World J Diabetes"},{"key":"7312_CR29","doi-asserted-by":"publisher","first-page":"1014857","DOI":"10.1155\/2020\/1014857","volume":"2020","author":"RS Al-Najjar","year":"2020","unstructured":"Al-Najjar RS, Al-Aubody N, Al-Asadi S, Alabbood M (2020) Pattern-reversal visual evoked potentials tests in persons with type 2 diabetes mellitus with and without diabetic retinopathy. Neurol Res Int 2020:1014857. https:\/\/doi.org\/10.1155\/2020\/1014857","journal-title":"Neurol Res Int"},{"key":"7312_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"7312_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"7312_CR32","doi-asserted-by":"publisher","first-page":"e2348431","DOI":"10.1001\/jamanetworkopen.2023.48431","volume":"6","author":"FS Yen","year":"2023","unstructured":"Yen FS, Wei JCC, Yu TS, Hung YT, Hsu CC, Hwu CM (2023) Sodium-glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes. JAMA Netw Open 6:e2348431. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.48431","journal-title":"JAMA Netw Open"},{"key":"7312_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivar Behav Res"},{"key":"7312_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3692-2","volume-title":"Observational studies","author":"PR Rosenbaum","year":"2002","unstructured":"Rosenbaum PR (2002) Observational studies, 2nd edn. Springer, New York. https:\/\/doi.org\/10.1007\/978-1-4757-3692-2","edition":"2"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07312-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:10:55Z","timestamp":1781241055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07312-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":34,"alternative-id":["7312"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07312-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any identifiable personal data or individual patient images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This prospective, non-interventional observational comparative study was approved by the institutional ethics committee (Approval No. A8670771-514.09, June 2022) and by the Turkish Medicines and Medical Devices Agency of the Ministry of Health of the Republic of T\u00fcrkiye (Approval No. 66175679-514.05.01-775220, June 2022). All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}